SARS-CoV-2 rapid antigen test clinical collaboration
Avacta and Liverpool School of Tropical Medicine collaborate to clinically validate saliva-based rapid coronavirus test being developed with Cytiva
Avacta and Liverpool School of Tropical Medicine collaborate to clinically validate saliva-based rapid coronavirus test being developed with Cytiva
Test delivers results in just 15 minutes with no instrumentation, using proven lateral flow technology with demonstrated sensitivity of 97.1% and specificity of 98.5%
First participants dosed in trial of AZD7442 to assess safety, tolerability and pharmacokinetics of the combination
The real-time PCR workflow has a capacity of up to 6,000 tests per day per system, and demonstrated 100% agreement with authorized nasopharyngeal assays
QIAseq SARS-CoV-2 Primer Panel converts viral RNA samples into libraries ready for sequencing, whereas QIAGEN Digital Insights solutions support COVID-19 drug, vaccine and epidemiology research
Syndromic testing will streamline respiratory infection diagnosis as COVID-19 pandemic collides with start of flu season
The AI-Rad Companion Brain MR and Prostate MR measures volumetric changes in brain, and segments prostate for targeted biopsy under MRI and ultrasound fusion imaging respectively
The Somatom scanner is equipped with a forward-looking camera and motorized wheels, allowing a single technologist to navigate the device through hospital hallways
Access Anti-SARS-CoV-2 is an easy-to-use 10-minute test on a portable device that provides highly accurate results on total Ig antibodies
Across all populations, BNT162b2 administration was well tolerated with mild to moderate fever in fewer than 20% of the participants
The kits aim to detect traces of SARS-CoV-2 virus on surfaces such as plastics, ceramics and stainless steel
Regeneron will distribute REGN-COV2 in the U.S. and Roche will be responsible for distribution outside the U.S.
The AccuPlex SARS-CoV-2 molecular controls kit is designed to measure day-to-day assay performance and contains positive materials
The collaboration is the first larger scale production run of Apta-1 as a non-GMP material, intended for use in GLP toxicology studies
The test outperforms other molecular tests with a low detection limit of 15 GEC/reaction (250 GEC/ml of sample) and a robust control system
The consortium aims to determine the dynamics, function and potential for therapeutic intervention of the RNA and protein structures of SARS-CoV-2
IgM assay has 95.51% positive predictive value even when disease incidence is only 3%
The new assays are designed to enable turnaround times for next-generation sequencing results of less than 24 hours
Used to empower clinicians to quickly prescribe treatment regimens for multidrug-resistant TB, the test could help fill a critical gap that is jeopardizing global TB targets
Dr. Jeremy Hirota takes us through the technology behind his translational research program for respiratory health
Nirsevimab is the first potential passive immunisation for infants to demonstrate sustained protection across the entire RSV season with a single dose
In two clinical trials, Evrysdi improved motor function in people living with SMA over a broad spectrum of ages and levels of disease severity, including Types 1, 2, and 3 SMA
This collaboration will allow Tecan to expand its presence for these product lines and reach a wider customer base across the academic and biotech communities
The high-throughput system enables laboratories to double or even triple their testing capacity